

# Surgery Committee

**Friday, April 8, 2022  
2:15 PM - 4:15 PM PT**

## **Message From The Executive Officer**

*Lisa Kachnic, MD*

## **Pancreatic cancer: The radiologist's perspective. Where are we now?**

*Alexander Guimaraes, MD, PhD, FSAR, FSAB, FACR*

## **Trials / Projects in Development and Ongoing Trials**

1. Lanreotide for the prevention of postoperative pancreatic fistula  
*Jonathan G. Sham, MD*
2. A pragmatic randomized phase II/ III trial evaluating early total ablative therapy for patients with limited metastatic colorectal cancer: Evaluating radiation, ablation, and surgery (ERASur). An Alliance Trial.  
*Sepideh Gholami, MD*
3. Preoperative Chemotherapy and Immunotherapy for MSS colon cancer.  
*Maheswari Senthil, MD*
4. Randomized trial of neoadjuvant Gemcitabine/ nab-Paclitaxel/ Cisplatin versus FOLFIRINOX or Gemcitabine/ nab-Paclitaxel in locally advanced pancreas cancer.  
*Erkut Borazanci, MD*

## **Secondary Analysis Updates**

1. The Effect of Radiation Modality on Outcomes of Patients Receiving Adjuvant Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Secondary Analysis of SWOG 0809.  
*David P. Horowitz, MD*
2. Does Adjuvant Chemoradiation Benefit Patients with Lymph Node Positive Biliary Tract Cancers? A Secondary Analysis of SWOG 0809.  
*Sepideh Gholami, MD*
3. Prognostic Value of Perioperative Systemic Therapy Dose Density/ Intensity for Pancreatic Adenocarcinoma. A Secondary Analysis of SWOG 1505.  
*Sameer Patel, MD*